Wells Fargo & Company Viking Therapeutics, Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 60,261 shares of VKTX stock, worth $3.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,261

Previous 28,801 109.23%

Holding current value

$3.98 Million

Previous $535,000 823.55%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $547,404 - $2.97 Million	31,460 Added 109.23%	60,261 $4.94 Million
Q4 2023 Feb 09, 2024	SELL	$9.24 - $19.64 $896,982 - $1.91 Million	-97,076 Reduced 77.12%	28,801 $535,000
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $278,449 - $407,984	25,499 Added 25.4%	125,877 $1.39 Million
Q2 2023 Aug 15, 2023	BUY	$14.84 - $24.79 $140,727 - $235,083	9,483 Added 10.43%	100,378 $1.63 Million
Q1 2023 May 12, 2023	BUY	$8.08 - $17.33 $722,279 - $1.55 Million	89,391 Added 5943.55%	90,895 $1.51 Million

Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $832 - $2,876	306 Added 25.54%	1,504 $14,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $5,133 - $7,830	-2,013 Reduced 62.69%	1,198 $3,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $115,271 - $172,087	-54,631 Reduced 94.45%	3,211 $9,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $67,998 - $110,610	-22,666 Reduced 28.15%	57,842 $174,000
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $153,331 - $223,997	-33,333 Reduced 29.28%	80,508 $370,000
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $75,625 - $95,413	-13,553 Reduced 10.64%	113,841 $716,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $332,881 - $431,655	-64,139 Reduced 33.49%	127,394 $764,000
Q1 2021 May 13, 2021	SELL	$5.74 - $9.67 $602,292 - $1.01 Million	-104,929 Reduced 35.39%	191,533 $1.21 Million
Q4 2020 Feb 09, 2021	BUY	$5.3 - $6.71 $265,991 - $336,754	50,187 Added 20.38%	296,462 $1.67 Million
Q3 2020 Nov 05, 2020	SELL	$5.73 - $8.11 $56,526 - $80,005	-9,865 Reduced 3.85%	246,275 $1.43 Million
Q2 2020 Aug 13, 2020	BUY	$4.35 - $8.08 $127,172 - $236,218	29,235 Added 12.88%	256,140 $1.85 Million
Q1 2020 May 14, 2020	BUY	$3.45 - $7.95 $782,822 - $1.8 Million	226,905 New	226,905 $1.06 Million

Others Institutions Holding VKTX

# of Institutions

430

Shares Held

63.3M

Call Options Held

7.39M

Put Options Held

5.13M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.06B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Viking Therapeutics, Inc. Transaction History